Oak Ridge Investments’s Heron Therapeutics HRTX Stock Holding History

Oak Ridge Investments’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-146,436	Closed	-$838K	–	159
2022 Q1	$838K	Sell	146,436 -70,592	-33%	-$517K	0.09%	132
2021 Q4	$1.98M	Sell	217,028 -21,679	-9%	-$221K	0.17%	111
2021 Q3	$2.55M	Sell	238,707 -6,086	-2%	-$74.1K	0.22%	107
2021 Q2	$3.8M	Sell	244,793 -22,106	-8%	-$352K	0.33%	100
2021 Q1	$4.33M	Buy	266,899 +484	+0.2%	+$8.63K	0.4%	92
2020 Q4	$5.64M	Sell	266,415 -67,086	-20%	-$1.17M	0.5%	78
2020 Q3	$4.94M	Sell	333,501 -27,640	-8%	-$431K	0.38%	93
2020 Q2	$5.31M	Sell	361,141 -24,588	-6%	-$404K	0.45%	83
2020 Q1	$4.53M	Buy	385,729 +145,705	+61%	+$2.74M	0.46%	82
2019 Q4	$5.64M	Sell	240,024 -25,780	-10%	-$570K	0.41%	88
2019 Q3	$4.92M	Buy	265,804 +157,309	+145%	+$2.9M	0.37%	89
2019 Q2	$2.02M	Sell	108,495 -22,848	-17%	-$456K	0.14%	111
2019 Q1	$3.21M	Buy	+131,343	New	+$3.44M	0.2%	117

Other funds holding HRTX

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Oak Ridge Investments's HRTX Position: Q2 2022 in Review

Oak Ridge Investments sold out of Heron Therapeutics (HRTX) in Q2 2022, closing a stake of 146,436 shares — an estimated $838K sold.

Oak Ridge Investments first reported a position in HRTX in Q1 2019 and held it in 13 quarters. The position peaked at $5.64M in Q4 2019. 174 funds tracked by Wall St. Rank hold HRTX as of Q2 2022.

Oak Ridge Investments reported no remaining Heron Therapeutics position as of Q2 2022 after selling out during the quarter.
Oak Ridge Investments sold 146,436 Heron Therapeutics shares in Q2 2022, an estimated $838K.
Oak Ridge Investments first reported a position in Heron Therapeutics in Q1 2019 and held it in 13 quarters.
Oak Ridge Investments's Heron Therapeutics position peaked at $5.64M in Q4 2019.
174 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2022.

Based on Oak Ridge Investments's 13F filing for Q2 2022, filed 28 Jul 2022.